Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Capital Expenditures (2016 - 2025)

Zevra Therapeutics' Capital Expenditures history spans 10 years, with the latest figure at -$31000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures changed N/A year-over-year to -$31000.0; the TTM value through Dec 2025 reached $835000.0, changed N/A, while the annual FY2025 figure was $835000.0, N/A changed from the prior year.
  • Capital Expenditures reached -$31000.0 in Q4 2025 per ZVRA's latest filing, down from $554000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $554000.0 in Q3 2025 to a low of -$31000.0 in Q4 2025.
  • Average Capital Expenditures over 4 years is $82875.0, with a median of $28500.0 recorded in 2022.
  • The largest YoY upside for Capital Expenditures was 2000.0% in 2021 against a maximum downside of 63.64% in 2021.
  • A 4-year view of Capital Expenditures shows it stood at $17000.0 in 2021, then skyrocketed by 100.0% to $34000.0 in 2022, then surged by 111.76% to $72000.0 in 2023, then plummeted by 143.06% to -$31000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Capital Expenditures are -$31000.0 (Q4 2025), $554000.0 (Q3 2025), and $213000.0 (Q2 2025).